EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSHCOG00000018490
Gene Symbol: GRIK1
3 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSHCOG00000021146
Gene Symbol: GRIK2
4 Cross references
240 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSHCOG00000010774
Gene Symbol: GRIK2
4 Cross references
253 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSHCOG00000006208
Gene Symbol: GRIK3
4 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSHCOG00000016865
Gene Symbol: GRIK4
3 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSHCOG00000011855
Gene Symbol: GRIK5
3 Cross references
232 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSHCOG00000004717
Gene Symbol: GRM2
3 Cross references
207 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSHCOG00000001550
Gene Symbol: GRM4
3 Cross references
207 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSHCOG00000020506
Gene Symbol: GRM4
3 Cross references
196 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSHCOG00000014839
Gene Symbol: GRM5
3 Cross references
216 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSHCOG00000002856
Gene Symbol: LOC109524392
3 Cross references
251 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSHCOG00000013046
Gene Symbol: LOC109516917
2 Cross references
249 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).